Hemab Therapeutics, a clinical-stage biotech company focused on blood coagulation disorder therapies, announced its management will participate in the 2026 Jefferies Global Healthcare Conference on November 17 and the 9th Annual Evercore Healthcare Conference on December 1. These events provide Hemab an opportunity to update investors on its innovative pipeline, including treatments for Glanzmann thrombasthenia, Von Willebrand Disease, and heavy menstrual bleeding. Live webcasts of the presentations will be available on Hemab's website, helping investors stay informed on the company's progress and future plans.
Hemab Therapeutics is in the spotlight as healthcare investors prepare for upcoming conferences. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 11, 2026 19:11 WIB: out of 150 priced US health stocks, 67 rose and 75 fell today. Notable movers include Medline Inc. (MDLN) at USD 39.71 with a 2.93% decline, Butterfly Network Inc. (BFLY) at USD 6.70 up 2.92%, and Relay Therapeutics Inc. (RLAY) at USD 20.48 up 2.71%.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
